94th Vifor Pharma Group Annual General Meeting

94^th Vifor Pharma Group Annual General Meeting

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

• Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions
• Dividend of CHF 2.00 approved
• All Board members re-elected and Conditional Board of Directors appointed, effective as from the date of the settlement of the tender offer by CSL Behring AG

ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News:

At today’s 94^th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. The Annual General Meeting was again held in accordance with the Ordinance 3 and the COVID-19 Act and has been reconfirmed in view of the current status of the tender offer launched by CSL Behring AG. Shareholders exercised their rights exclusively through the independent proxy.

Shareholder approvals
Shareholders approved the Annual Report and the Annual Financial Statements of Vifor Pharma Ltd. and the consolidated Financial Statements of Vifor Pharma for 2021 by a large majority, as well as the 2021 Remuneration Report in a consultative vote. In addition, shareholders discharged the members of the Board of Directors and the Executive Committee for the business year 2021. A dividend of CHF 2.00, as proposed by the Board of Directors, was approved and will be paid to shareholders from 3 May 2022 on.

Re-election of Board of Directors
The Annual General Meeting confirmed Chairman Jacques Theurillat and the other members of the Board of Directors, Prof. Hon. Dr. Michel Burnier, Dr. Romeo Cerutti, Dr. Alexandre LeBeaut, Dr. Sue Mahony, Åsa Riisberg and Kim Stratton in office, as well as Dr. Sue Mahony (Chair), Prof. Hon. Dr. Michel Burnier and Dr. Romeo Cerutti to the Remuneration Committee.

Conditional new elections to the Board, effective as from settlement date
In addition, the Annual General Meeting conditionally elected Paul McKenzie (elected Chairman), Greg Boss, John Levy, Joy Linton, Markus Stämpfli and Elizabeth Walker as new members of the Board of Directors, to become effective as from the date of settlement under the terms of the tender offer of CSL Behring AG as of 18 January 2022. Greg Boss, Joy Linton and Elizabeth Walker have been conditionally elected to the Remuneration Committee.

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency and nephrology. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions across iron, dialysis, nephrology and rare conditions. Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and includes the companies: Vifor Pharma, Sanifit Therapeutics, and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com